Mobile

A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multip...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005088-82

A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To assess the efficacy of multiple oral doses of AFQ056 in reducing the global score of the Aberrant Behavior Checklist – Community Edition (ABC-C) in FXS patients. - To assess the safety and tolerability of multiple titrated oral doses of AFQ056 in FXS patients.

Critère d'inclusion

  • Fragile X syndrome

Liens